The FDA says it won't recommend new limits on Eli Lilly ($LLY) schizophrenia med Zyprexa Relprevv after almost a year of investigating the deaths of two patients 3 to 4 days after they received injections. The agency finished reviewing a study designed to determine why the two patients had extremely high levels of Zyprexa Relprevv in their blood. According to an FDA safety alert, the study suggested much of the increase in drug levels could have occurred after death. But the results of the study were "inconclusive," the agency said.